Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate

Exclusion criteria

• ✕. Small cell lung cancer (including small lung cancer mixed with non-small cell lung cancer)
• ✕. Patients at risk of bleeding treated with antiangiogenic drugs
• ✕. Subjects who are using immunosuppressive agents, or systemic, or absorbable topical hormone therapy for immunosuppressive purposes (dose \>10mg/ dprednisone or other therapeutic hormones) and who continue to use it for 2 weeks prior to enrollment
• ✕. Patients with active, known or suspected autoimmune diseases, including tuberculosis, HIV infection, active hepatitis, etc.
• ✕. Patients with previous and current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radioactive pneumonia, drug-related pneumonia, severe impairment of lung function, etc
• ✕. Women who are pregnant or lactating, or who are unwilling to use contraception during the trial